GT BIOPHARMA INC
GTBP · NASDAQ
Updated at 2026-10-13 15:18:11
- Today's High
- $7.52
- Today’s Low
- $6.46
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $6.79
- Previous Close
- $6.80
- Volume
- 37.95K
- Market Cap
- $14.01M
- P/E Ratio
- --
- EPS
- $-47.50
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 315 MONTGOMERY STREET, SAN FRANCISCO, CA, UNITED STATES, 94104
- Country
- US
- Listing Date
- 2013-10-22
- Fiscal Year End
- December
- Shares Outstanding
- 44.34M
- CIK
- 0000109657
- Website
- www.gtbiopharma.com
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
Financial Metrics
Revenue
2026-06-30
--
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$4.51M
2026-03-31
$2.84M
2025-12-31
$5.59M
2025-09-30
$3.38M
Net Income
2026-06-30
-$4.51M
2026-03-31
-$2.83M
2025-12-31
-$23.03M
2025-09-30
$8.29M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.12
2026-03-31
$-0.11
2025-12-31
$-121.00
2025-09-30
$-0.83
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$4.45M
2026-03-31
-$2.77M
2025-12-31
-$21.4M
2025-09-30
$8.29M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | -- | $0 | $0 | $0 |
| Operating Expenses | $4.51M | $2.84M | $5.59M | $3.38M |
| Net Income | -$4.51M | -$2.83M | -$23.03M | $8.29M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.12 | $-0.11 | $-121.00 | $-0.83 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$4.45M | -$2.77M | -$21.4M | $8.29M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.